Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7Genitourinary 3Head & Neck 2Thoracic 1NET 1Endocrine 1Dermatologic 1

Conditions

Melanoma 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Hypoxia 1

Interventions

pembrolizumab 16Cyclophosphamide 8Nivolumab 7Gemcitabine 6Paclitaxel 5Drug Therapy 5Docetaxel 5fludarabine 4aldesleukin 4Oxaliplatin 4Fluorouracil 4Carboplatin 4ulixertinib 3spartalizumab 3Trastuzumab 3Radiotherapy 3Leucovorin 3Capecitabine 3trametinib 2tovorafenib 2pertuzumab 2pegilodecakin 2pazopanib 2palbociclib 2osimertinib 2enzalutamide 2cemiplimab 2atezolizumab 2Taxes 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × TH 302 × Dermatologic × Clear all
NCT03098160 2017-10-30

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Threshold Pharmaceuticals

Phase 1 Unknown
69 enrolled
DermatologicGastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Hypoxia, Melanoma, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡